A publication from Acta Pharmaceutica Sinica B discusses the structure-based development of potent and selective type-II kinase inhibitors of RIPK1. Receptor-interacting serine/threonine-protein ...
A Parkinsonian mystery—how PINK1 locks onto malfunctioning mitochondria—now has a structural solution. Researchers at the University of Melbourne led by Sylvie Callegari, Alisa Glukhova, and David ...
Researchers provide essential insights on the molecular activation of the MAP kinase p38?, the final switch triggering the inflammatory response. Inflammation is a cellular coping mechanism when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results